European Comission Approves Vyndaqel for Treating Cardiomyopathy in Adults with Transthyretin Amyloidosis
The European Commission (EC) has approved the once-daily oral medication Vyndaqel (tafamidis) for the treatment of cardiomyopathy — a disease of the heart muscle that makes it harder for the heart to pump blood to the rest of the body — in adults with transthyretin…